Industry to offer optional risk mitigation CE for pain relievers to practitioners

February 15, 2013

Health care practitioners in March will begin receiving offers of free, industry-sponsored continuing education (CE), as part of the U.S. Food and Drug Administration’s (FDA) new Risk Evaluation and Mitigation Strategy (REMS). This is designed to ensure the benefits of extended-release (ER) and long-acting (LA) opioids, such as Vicodin, Percodin, and Percoset, outweigh any risks.

Although drug makers are mandated to provide the education, health care practitioners will not be required to attend.

For additional information, visit www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM277916.pdf.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: